Airbus recorded orders and options for 123 planes, according to the aviation consulting firm IBA.iQ.Airlinesread more
Wall Street analysts think Facebook's cryptocurrency payments project will give the company a big boost.Marketsread more
Facebook's reported move into cryptocurrency could amount to the biggest catalyst for digital assets in their decade-long history, some crypto investors say.Bitcoinread more
In a 7-2 ruling, over dissents from Justices Ruth Bader Ginsburg and Neil Gorsuch, the justices affirmed the so-called "dual sovereignty" exception to the Constitution's...Politicsread more
A recent Fed survey showed that workers' confidence for finding a new job after losing their current position was at 61.5% in May.Economyread more
The Fed is expected to cut rates multiple times, but the reason behind those cuts could have vastly different implications for the market.Marketsread more
The "captive carry flight test" evaluates the mock weapon during flight and is the Air Force's latest step amid the budding hypersonic arms race between China and Russia.Politicsread more
"This is going to be the biggest thing that's happened to Facebook in years," says CNBC's Jim Cramer. "It will be vital."Investingread more
European aircraft manufacturer Airbus is betting travelers will want to fly long distances on smaller jets with the launch of its Airbus A321 XLR.Airlinesread more
The action reflects the evolving dynamic for U.S. companies that have done business with Huawei, which has been caught in the middle of growing U.S.-China trade tension.Technologyread more
The announcement comes after Trump blasted three countries because thousands of their citizens had sought asylum at the U.S. border with Mexico.Politicsread more
The Trump administration's plan to lower drug prices didn't appear as damaging as some had feared — at least the ones they're pushing now. The bigger threats could come later.
President Donald Trump unveiled his blueprint to lower drug prices, called "American Patients First," in a highly anticipated speech on Friday. However, his actions weren't as biting as his words suggested.
The proposal included few immediate actions the administration would take but none that would bring any massive reforms. Wall Street welcomed the letdown, relieving health-care stocks of the pressure they had been feeling.
However, the clouds haven't cleared yet, Evercore analysts Ross Muken and Michael Newshel said in a note to clients following Trump's speech.
They pointed to future possibilities listed in the proposal that could hurt pharmacy benefit managers, or PBMs, which negotiate discounts with manufacturers. They included restricting the use of these rebates, revisiting whether statutes that currently allow the practice and considering fiduciary status for the firms. This designation would require companies to work on behalf of patients' best interest.
"At this point it's still a threat, and now the question is whether the administration follows through or not on actions that could pose bigger risks to the drug channel," Muken and Newshel said.
In his speech, Trump railed against middlemen for becoming "very, very rich," saying they "won't be so rich anymore" and the administration is "very much eliminating them."
In a press briefing following the speech, Health and Human Services Secretary Alex Azar said the administration is calling into question the entire system of rebates as the method of negotiating discounts in the pharmacy channel.
"Because right now, every incentive is for the drug company to have a very high list price and to negotiate list price down, often in a very nontransparent way," Azar said.
The Pharmaceutical Care Management Association, which represents the PBM industry, said getting rid of rebates would leave patients and payers "at the mercy of drug manufacturer pricing strategies."
"PBMs have long encouraged manufacturers to offer payers alternative ways to reduce net costs," the group said in a statement. "Simply put, the easiest way to lower costs would be for drug companies to lower their prices."